世界のゲノミクス関連の提携条件・契約：2016年～2023年

当レポートでは、世界のゲノミクス関連市場における提携契約の動向と条件について調査分析し、最近の動向、代表的な取引の概要、活発な事業者、提携契約ディレクトリ、主要取引 (金額別) などについて、体系的な情報を提供しています。

目次

エグゼクティブサマリー

第1章 イントロダクション

第2章 ゲノミクス関連の契約動向

• イントロダクション
• 過去数年間の提携
• 最も活発な事業者
• ゲノミクス関連の提携契約：取引タイプ別
• ゲノミクス関連の提携契約：治療分野別
• ゲノミクス関連の提携契約：業界部門別
• ゲノミクス関連の取引条件
  • 取引総額
  • 前金支払額
  • 目標達成報奨金
  • ロイヤルティ料率
• ゲノミクス取引の構造
• a. ケーススタディ1：RRD International & Dipexium Pharmaceuticals
• b. ケーススタディ2：Hospira & Cempra Pharmaceutical
• c. ケーススタディ3：Astellas & Optimer Pharmaceuticals

第3章 主要なゲノミクス関連の取引

• イントロダクション
• 主要取引：金額別

第4章 最も活発なゲノミクス関連の事業者

• イントロダクション
• 最も活発な事業者
• 最も活発な事業者のプロファイル

第5章 ゲノミクス関連の契約ディレクトリ

• イントロダクション
• ゲノミクス関連の契約ディレクトリ

第6章 ゲノミクス関連の契約：技術タイプ別

第7章 提携リソースセンター

• オンライン提携
• 提携イベント
• 参考文献

付録

Description

Genomic Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the genomic deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of genomic deals from 2016 to 2023.

The report provides a detailed understanding and analysis of how and why companies enter genomic deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 857 genomic deals announced since 2016 including financial terms where available including links to online deal records of actual genomic partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of genomic dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in genomic dealmaking since 2016.

Chapter 3 provides an overview of the leading genomic deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in genomic dealmaking with a brief summary followed by a comprehensive listing of genomic deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of genomic deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of genomic partnering deals signed and announced since Jan 2016. The chapter is organized by specific genomic technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in genomic deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Genomic Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse genomic collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Genomic Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of genomic trends and structure of deals entered into by leading biopharma companies worldwide.

Genomic Collaboration and Licensing Deals includes:

• Trends in genomic dealmaking in the biopharma industry
• Directory of genomic deal records covering pharmaceutical and biotechnology
• The leading genomic deals by value
• Most active genomic licensing dealmakers
• Genomic Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Benefits

Genomic Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse genomic collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in genomic dealmaking

• 2.1. Introduction
• 2.2. Genomic deals over the years
• 2.3. Most active genomic dealmakers
• 2.4. Genomic deals by deal type
• 2.5. Genomic deals by therapy area
• 2.6. Genomic deals by industry sector
• 2.7. Deal terms for genomic deals
  • 2.7.1 Genomic deals headline values
  • 2.7.2 Genomic deal upfront payments
  • 2.7.3 Genomic deal milestone payments
  • 2.7.4 Genomic royalty rates

Chapter 3 - Leading genomic deals

• 3.1. Introduction
• 3.2. Top genomic deals by value

Chapter 4 - Most active genomic dealmakers

• 4.1. Introduction
• 4.2. Most active genomic dealmakers
• 4.3. Most active genomic deals company profiles

Chapter 5 - Genomic contracts dealmaking directory

• 5.1. Introduction
• 5.2. Genomic contracts dealmaking directory

Chapter 6 - Genomic dealmaking by technology type

• Deal directory
• Deal directory - Genomic deals by company A-Z
• Deal directory - Genomic deals by deal type
• Deal directory - Genomic deals by therapy area
• Deal type definitions
• About Wildwood Ventures
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering
•  

Table of figures

• Figure 1: Genomic deals since 2016
• Figure 2: Active genomic dealmaking activity - 2016 - 2023
• Figure 3: Genomic deals by deal type since 2016
• Figure 4: Genomic deals by therapy area since 2016
• Figure 5: Genomic deals by industry sector since 2016
• Figure 6: Genomic deals with a headline value
• Figure 7: Genomic deals with an upfront value
• Figure 8: Genomic deals with a milestone value
• Figure 9: Genomic deals with a royalty rate value
• Figure 10: Top genomic deals by value since 2016
• Figure 11: Most active genomic dealmakers 2016 - 2023
• Figure 12: Genomic deals by technology type since 2016